Appropriate risk criteria for OATP inhibition at the drug discovery stage based on the clinical relevancy between OATP inhibitors and drug-induced adverse effect

Masanori Nakakariya

[1-G-P-6] Appropriate risk criteria for OATP inhibition at the drug discovery stage based on the clinical relevancy between OATP inhibitors and drug-induced adverse effect

^○Masanori Nakakariya , Akihiko Goto , Nobuyuki Amano (Drug Metabolism & Pharmacokinetics Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

Best Poster Award Finalists

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.

Presentation information

ポスター発表G会場

[1-G-P-6] Appropriate risk criteria for OATP inhibition at the drug discovery stage based on the clinical relevancy between OATP inhibitors and drug-induced adverse effect

Password